<DOC>
	<DOCNO>NCT01379274</DOCNO>
	<brief_summary>This phase II study evaluate safety efficacy combine two active agent ; Revlimid® ( lenalidomide ) low dose Vidaza® ( azacitidine ) treatment patient low intermediate-1 MDS exclude patient 5 q deletion . The rationale add Vidaza® ( azacitidine ) 3 month revlimid monotherapy combination therapy result high response rate , potentially long response duration achieve either agent . STUDY OBJECTIVES : Primary : To determine safety tolerability combination Revlimid® ( lenalidomide ) low dose Vidaza® ( azacitidine ) patient low - intermediate-1 risk MDS non 5 q deletion respond 3 month Revlimid® ( lenalidomide ) monotherapy Secondary : To determine response rate patient low - intermediate-1 risk MDS non 5 q deletion receive Revlimid® ( lenalidomide ) combination low dose Vidaza® ( azacitidine ) , define IWG 2006 Revised Response Criteria</brief_summary>
	<brief_title>A Trial Lenalidomide &amp; Azacitidine Low Risk Myelodysplastic Syndromes</brief_title>
	<detailed_description>Eligibility criterion 1 . Understand voluntarily sign informed consent form . 2 . Age 18 year time signing informed consent form . 3 . Able adhere study visit schedule protocol requirement . 4 . Diagnosis low- intermediate-1-risk IPSS ( see Appendix III ) MDS without abnormality chromosome 5 involve deletion band q31 q33 . Pathologic diagnosis via pathology perform Rush University Medical Center make available Rush outside institution . 5 . Prior treatment &lt; 3 cycle ( 84 day ) Revlimid® ( lenalidomide ) eligible enrollment regardless response . 6 . ECOG performance status 2 study entry ( see Appendix II ) . 7 . Disease free prior malignancy &gt; 5 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` insitu '' cervix breast . 8 . Serum bilirubin level &lt; 1.5 time upper limit normal range laboratory ( ULN ) . Higher level acceptable attribute active hemolysis ineffective erythropoiesis . 9 . Serum glutamic-oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) serum glutamic-pyruvic transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) level &lt; 2 x ULN . 10 . Serum creatinine level &lt; 1.5 x ULN 11 . Absolute neutrophil count &gt; 1000/mm³ 12 . Platelet count &gt; 30,000/mm³ 13 . All study participant must register mandatory RevAssist® program , willing able comply requirement RevAssist® .</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Patients low Int1 risk MDS 1 . ECOG performance status &lt; 2 study entry ( see Appendix II ) . 2 . Disease free prior malignancy 5 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` insitu '' cervix breast . 3 . Serum bilirubin level &lt; 1.5 time upper limit normal range laboratory ( ULN ) . Higher level acceptable attribute active hemolysis ineffective erythropoiesis . 4 . Serum glutamicoxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) serum glutamicpyruvic transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) level &lt; 2 x ULN . 5 . Serum creatinine level 1.5 x ULN 6 . Absolute neutrophil count &gt; 1000/mm³ 7 . Platelet count &gt; 30,000/mm³ 8 . All study participant must register mandatory RevAssist® program , willing able comply requirement RevAssist® . 9 . Females childbearing potential ( FCBP ) † must negative serum urine 1 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . 2 . Pregnant breast feeding female . Lactating female must agree breast feed take Revlimid® ( lenalidomide ) . 3 . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . 4 . Use experimental drug therapy within 28 day baseline . 5 . Known hypersensitivity lenalidomide , azacitidine , mannitol . 6 . Any prior use Vidaza® ( azacitidine ) . 7 . Prior use Revlimid® ( lenalidomide ) 84 day ( three 28 day cycle ) . 8 . Concurrent use anticancer agent treatment . 9 . Known positive HIV infectious hepatitis , type B C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>MDS</keyword>
	<keyword>Low risk disease</keyword>
	<keyword>IPSS</keyword>
</DOC>